Dr. Kinneret Livnat Savitzky is the Director / Chairperson at a variety of biotech entities, and Held director / chairperson position in a number of companies and organizations including BioLineRx, ILSI, Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), Compugen Ltd., KAHR medical, DreaMed Diabetes, Biomica, Hadasit, FutuRx and its portfolio companies.

She is also serving as the Chief Executive Officer and Board member of FutuRx, an Israeli biotechnology accelerator established by OrbiMed Israel Partners, Johnson & Johnson Innovation and Takeda Ventures Inc., with the office of the Israeli Innovation Authority (IIA). Recently Bayer’s venture arm LEAPS joined as a partner in FutuRx as well.

Before that she served as Chief Executive Officer of BioLineRx, General Manager of Bioline Innovations Jerusalem (BIJ) Between the years 2005 – 2009, VP of drug development, BiolineRx Between 2004 – 2005.

Between the years 1997 – 2004 Dr. Savitzky held several positions, the last of which being Vice President of Biology at Compugen Ltd. Besides the Biology R&D, was involved in collaborations with global pharmaceutical companies.

Dr. Savitzky holds the titles: Ph.D. with distinction in Human Genetics from Tel Aviv University, Master’s degree in human genetics from Tel Aviv University and B.Sc. in Biology from The Hebrew University of Jerusalem.